Revvity, Inc. (RVTY) · Nov 3, 2026 · Earnings

Revvity earnings beat as organic growth accelerates and guidance rises

Beat — Adjusted EPS $1.38 vs ~$1.30 consensus

Revvity’s Q3 earnings beat expectations, powered by 7% organic growth and expanding margins, while full-year guidance moved modestly higher.

Revvity is in the middle of a transformation from a recently pressured life-sciences and diagnostics portfolio toward steadier organic growth, better operating leverage, and a smaller China diagnostics footprint. Its prior full-year 2026 framework called for $2.83–$2.86 billion of revenue, 4%–5% organic growth, and $5.30–$5.40 of adjusted EPS, so the key question was whether the recovery was becoming broad and durable.

The quarter cleared expectations on both earnings and revenue. Adjusted EPS was $1.38, ahead of the published consensus of roughly $1.30, while revenue reached $728.9 million versus expectations near $695 million; pro forma revenue was $709.6 million. The filing also reports 7% pro forma organic growth, compared with the 4%–5% full-year target previously in place.

Q3 2026Q3 2025Consensus
Revenue (Financial Highlights)$728.9M (+4.3%)$698.9M~$694.7M
Adjusted EPS (Supplemental information)$1.38 (+16.9%)$1.18~$1.30
Pro forma organic growth (Organic revenue growth)7%——
Adjusted operating margin (Revenue and adjusted operating income)28.7% (+2.6 pts)26.1%—

The improvement is becoming more balanced, led by Life Sciences but no longer dependent on it alone. Life Sciences revenue rose 11% pro forma and 9% organically, with adjusted operating margin expanding to 31.5% from 29.5%. Diagnostics revenue was down 2% on a reported basis, but its pro forma organic revenue grew 5% and its margin jumped to 29.9% from 25.1%.

The guidance move is positive, but incremental rather than transformational. Revvity now expects approximately $2.86 billion of pro forma revenue, roughly 5% organic growth, and $5.40–$5.45 of adjusted EPS, lifting the EPS range above the prior $5.30–$5.40 framework and placing the midpoint modestly above the published consensus near $5.35. The raised outlook validates the recovery, but the revenue ceiling is only at the top of the previous range rather than a major reset.

The reported numbers still contain a meaningful restructuring burden, but the underlying operating trend is stronger. Quarterly restructuring and other charges rose to $28.4 million from $9.9 million, yet adjusted operating income increased to $209.3 million and adjusted margin expanded to 28.7%. That makes the improvement more credible as operating execution, while also showing that the transformation is not yet finished. The China Immunodiagnostics divestiture remains a known background item, representing about 6% of 2025 revenue and expected to close by the end of 2027; the pro forma presentation removes that business from the forward outlook.

Bottom line: This is a clear earnings beat with broadening organic growth, better margins, and a modestly higher full-year outlook. It strengthens Revvity’s recovery story without rewriting it; the November 13 Investor Day is the next test of how much of this improvement management believes can persist.

What to watch next

Investor Day, November 13, 2026

Original filing on SEC EDGAR

More Revvity, Inc. news

Revvity earnings beat as organic growth accelerates and guidance rises | RVTY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.